DiaMedica reports FY2025 cash $59.9M; ReMEDy2 trial nearing 70% interim enrollment

DiaMedica Therapeutics Inc.

Cash and investments $59.9M at Dec 31, 2025, up from $44.1M; runway through 2H 2027.
ReMEDy2 Phase 2/3 AIS trial approaching 70% of required interim enrollment; analysis in 2H 2026.
R&D expenses $24.6M vs $19.1M YoY driven by ReMEDy2 expansion and PE program costs.
G&A expenses $9.8M vs $7.6M YoY; net cash used in ops $29.1M vs $22.1M.
PE Phase 2 IST Part 1a enrollment ongoing; DiaMedica-sponsored Phase 2 to start later 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

DiaMedica Therapeutics Inc. reported financial results for the year ended December 31, 2025.

Period: the year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 30, 2026, DiaMedica Therapeutics Inc. (the "Company") announced its consolidated financial results for the year ended December 31, 2025.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

DiaMedica Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-010409

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.